Attention, terrorist pigs @RussianEmbassyC:
The WJHC is happening in Canada.
We own the brand and the game itself.
You're banned from the tournament and will not be getting visas to enter the country.
Period. Stop.
You keep murdering, raping and kidnapping Ukrainians.
On behalf of Canada, Ukraine, and the rest of the free world, get fucked.
#SlavaUkraïni 🇺🇦🇨🇦
@Jn66039675 Only CALD and there they blame the vector AFAIK. But the risk is not zero even with lenti.
For me the AAV cancer cases are more concerning b/c with lenti you don't flood the nucleus with viral DNA. And AAV distributes to many sites.
@Jn66039675 IMO this can't be compared on the basis of absolute unique integrations. HSPC are much more prone to transformation vs T cells, and still very few malignancies.
@Jn66039675 My guess is millions of initial transduction events, which is still rare (around 0.1% at 1E9 TU dose), but serum/complement irrelevant, so Cocal and VSV both working fine. If blinding is needed? Genocury’s data would argue no, but more granular dose data needed.
@Jn66039675 Total T cells infected in vivo will need deeper and more longitudinal sampling but usually limited number of expanded clones (see eg Genocury NEJM paper).
@Jn66039675 PK very similar to ex vivo CAR-T. Cmax maybe a bit later (day 14-18 vs 10-14).
Cmax can reach >1E5 vcn/ug gDNA, corresponding to >1000 CAR-T cells/ul.
Low T cell counts and ALC as exclusion criteria.
Expansion may correlate w/ baseline tumor load, but datasets small.
$ACIU: Jefferies - ACI-19764 Phase 1b hsCRP data moved to 1H27 from 2H26 because of slower recruitment, while full NLRP3 results remain due in 2027. Prior healthy-volunteer work showed tolerability, CSF penetration and PK supporting 10 mg once daily. Cash of CHF 73.9M extends into Q1 2028, but the delay pushes the next meaningful clinical proof point farther out. Peers: NVS BIIB DNLI ALEC